6.1 Factors influencing drug and device pricing

Pricing drugs and medical devices is a complex balancing act. Companies must recoup massive R&D costs while considering market forces, competition, and value to patients. It's not just about slapping on a markup.

Intellectual property plays a huge role too. Patents give companies a window to charge higher prices before generics enter the market. But they have to maximize returns during that time to fund future innovations.

Production Costs

R&D and Manufacturing Expenses

Top images from around the web for R&D and Manufacturing Expenses

• 

  Frontiers | Computational Approaches in Preclinical Studies on Drug Discovery and Development View original

  Is this image relevant?

• 

  A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike ... View original

  Is this image relevant?

• 

  Frontiers | Discovering Anti-Cancer Drugs via Computational Methods View original

  Is this image relevant?

• 

  Frontiers | Computational Approaches in Preclinical Studies on Drug Discovery and Development View original

  Is this image relevant?

• 

  A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike ... View original

  Is this image relevant?

1 of 3

Top images from around the web for R&D and Manufacturing Expenses

• 

  Frontiers | Computational Approaches in Preclinical Studies on Drug Discovery and Development View original

  Is this image relevant?

• 

  A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike ... View original

  Is this image relevant?

• 

  Frontiers | Discovering Anti-Cancer Drugs via Computational Methods View original

  Is this image relevant?

• 

  Frontiers | Computational Approaches in Preclinical Studies on Drug Discovery and Development View original

  Is this image relevant?

• 

  A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike ... View original

  Is this image relevant?

1 of 3

• Research and development costs drive pharmaceutical pricing encompassing drug discovery, preclinical testing, and clinical trials
• Drug discovery process involves screening thousands of compounds to identify potential candidates
• Preclinical testing evaluates drug safety and efficacy in laboratory and animal studies
• Clinical trials consist of three phases testing drug safety and effectiveness in humans
  • Phase I: Small group of healthy volunteers to assess safety and dosage
  • Phase II: Larger group of patients to evaluate efficacy and side effects
  • Phase III: Large-scale testing to confirm effectiveness, monitor side effects, and compare to standard treatments
• Manufacturing costs include raw materials, equipment, quality control, and facility maintenance
• Good Manufacturing Practices (GMP) compliance increases production expenses
• Scale-up challenges from lab to commercial production impact costs (batch size differences, equipment requirements)

Marketing and Pricing Strategies

• Marketing expenses cover promotional activities, sales force, and educational programs
• Medical education programs inform healthcare providers about new treatments
• Direct-to-consumer advertising allowed in some countries (United States) increases marketing costs
• Cost-plus pricing calculates product price by adding a markup percentage to total costs
• Markup percentage varies based on industry norms and company goals
• Cost-plus pricing ensures profitability but may not reflect market demand or competition

Market Dynamics

Competitive Landscape and Demand Factors

• Competition influences pricing strategies in pharmaceutical and medical device markets
• Generic drug entry after patent expiration typically reduces prices
• "Me-too" drugs with similar mechanisms of action create price competition
• Demand elasticity measures how sensitive consumers are to price changes
  • Inelastic demand: Price changes have little effect on quantity demanded (life-saving drugs)
  • Elastic demand: Price changes significantly affect quantity demanded (lifestyle drugs)
• Market size affects pricing decisions and potential return on investment
• Orphan drugs for rare diseases often have higher prices due to smaller patient populations

Reimbursement and Value Considerations

• Reimbursement policies of public and private payers impact pricing decisions
• Health Technology Assessment (HTA) agencies evaluate cost-effectiveness of new treatments
• Value-based pricing sets prices based on perceived value to patients and healthcare systems
• Quality-Adjusted Life Year (QALY) measures health outcomes and cost-effectiveness
• Incremental Cost-Effectiveness Ratio (ICER) compares new treatments to existing options
  • ICER = $(Cost_{new} - Cost_{standard}) / (QALY_{new} - QALY_{standard})$
• Therapeutic value considers clinical benefits, safety profile, and quality of life improvements

Intellectual Property

Patent Protection and Market Exclusivity

• Patent protection grants exclusive rights to manufacture and sell a drug for a limited time
• Standard patent term lasts 20 years from filing date
• Effective patent life often shorter due to time spent in development and regulatory review
• Patent expiration allows generic competition and typically leads to price reductions
• Patent extension strategies include:
  • New formulations or delivery methods
  • Combination products
  • New indications for existing drugs
• Market exclusivity periods granted by regulatory agencies (FDA, EMA) provide additional protection
  • Orphan drug exclusivity: 7 years in US, 10 years in EU
  • New chemical entity exclusivity: 5 years in US
  • Pediatric exclusivity: Additional 6 months added to existing patents or exclusivity periods